Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| RVTY | REVVITY, INC. | 2026-03-03 12:07:25 | 93.11 | -2.48 | -2.59 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVTY | 0000031791 | REVVITY, INC. | US7140461093 | 549300IKL1SDPFI7N655 | 042052042 | NYSE | 3826 | Laboratory Analytical Instruments | 1229 | MA | 77 4TH AVENUE | WALTHAM | MA | 02451 | UNITED STATES | US | 781-663-6900 | 77 4TH AVENUE, WALTHAM, MA, 02451 | 77 4TH AVENUE, WALTHAM, MA, 02451 | PERKINELMER INC | Biotechnology | 2023-05-09 | Prahlad Singh | 11,000 | http://revvity.com | 12,871,238,120 | 112,281,000 | 111,799,374 | Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines. | 2026-02-26 16:05:13 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 11,298,522,046 | -1,572,716,074 | -12.2188 | 111,799,374 | -8,387,912 | -6.979 |
| 2024 | 12,871,238,120 | -1,826,542,602 | -12.4273 | 120,187,286 | -3,342,535 | -2.7059 |
| 2023 | 14,697,780,722 | -3,391,865,131 | -18.7503 | 123,529,821 | -2,882,164 | -2.28 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Joel S. Goldberg | Secretary, General Counsel, Senior Vice President | 2024 | 550,000 | 0 | 1,031,208 | 732,188 | 39,086 | 3,381,566 |
| Miriame Victor | Chief Commercial Officer, Senior Vice President | 2024 | 467,692 | 0 | 727,508 | 530,299 | 26,166 | 2,477,646 |
| Prahlad R. Singh | Chief Executive Officer | 2024 | 1,100,000 | 0 | 4,125,038 | 2,530,440 | 54,839 | 11,926,615 |
| Maxwell Krakowiak | Chief Financial Officer, Senior Vice President | 2024 | 507,692 | 0 | 1,050,013 | 615,038 | 25,168 | 3,245,686 |
| Tajinder S. Vohra | Senior Vice President | 2024 | 475,000 | 0 | 653,115 | 504,189 | 25,311 | 2,309,353 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 11,000 |
| 2024 | 11,000 |
| 2023 | 16,700 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 2,856,051,000 | 2,755,026,000 | 2,750,571,000 |
| Cost Of Revenue | 1,117,132,000 | 1,041,749,000 | 1,077,744,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 215,840,000 | 196,844,000 | 216,578,000 |
| General And Administrative Expenses | 991,890,000 | 994,074,000 | 1,022,551,000 |
| Operating Expenses | — | — | — |
| Operating Income | 356,635,000 | 346,741,000 | 300,562,000 |
| Net Income | 241,201,000 | 270,385,000 | 693,094,000 |
| Earnings Per Share Basic | 2.07 | 2.21 | 5.56 |
| Earnings Per Share Diluted | 2.07 | 2.2 | 5.55 |
| Weighted Average Shares Outstanding Basic | 116,542,000 | 122,756,000 | 124,704,000 |
| Weighted Average Shares Outstanding Diluted | 116,595,000 | 122,822,000 | 124,812,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 919,860,000 | 1,163,396,000 | 913,163,000 |
| Marketable Securities Current | — | 0 | 689,916,000 |
| Accounts Receivable | 782,679,000 | 660,563,000 | 662,404,000 |
| Inventories | 379,497,000 | 367,587,000 | 428,062,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 195,719,000 | 186,225,000 | 337,139,000 |
| Total Assets Current | 2,239,747,000 | 2,349,608,000 | 3,001,091,000 |
| Marketable Securities Non Current | 27,956,000 | 27,413,000 | 13,913,000 |
| Property Plant And Equipment | 479,249,000 | 482,217,000 | 509,654,000 |
| Other Assets Non Current | 323,480,000 | 288,397,000 | 342,966,000 |
| Total Assets Non Current | 749,031,000 | 745,880,000 | 758,876,000 |
| Total Assets | 12,168,411,000 | 12,392,478,000 | 13,564,665,000 |
| Accounts Payable | 185,464,000 | 167,463,000 | 204,121,000 |
| Deferred Revenue | 160,194,000 | 140,212,000 | 135,555,000 |
| Short Term Debt | 588,828,000 | 242,000 | 721,872,000 |
| Other Liabilities Current | 556,954,000 | 485,395,000 | 524,470,000 |
| Total Liabilities Current | 1,331,246,000 | 653,100,000 | 1,450,463,000 |
| Long Term Debt | 2,631,236,000 | 3,150,476,000 | 3,899,642,000 |
| Other Liabilities Non Current | 807,461,000 | 770,523,000 | 930,946,000 |
| Total Liabilities Non Current | 3,586,805,000 | 4,072,504,000 | 4,241,463,000 |
| Total Liabilities | 4,918,051,000 | 4,725,604,000 | 5,691,926,000 |
| Common Stock | 112,281,000 | 120,646,000 | 123,426,000 |
| Retained Earnings | 6,054,314,000 | 5,845,223,000 | 5,609,212,000 |
| Accumulated Other Comprehensive Income | -222,135,000 | -396,105,000 | -276,692,000 |
| Total Shareholders Equity | 7,250,360,000 | 7,666,874,000 | 7,872,739,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 405,340,000 | 427,849,000 | 431,769,000 |
| Share Based Compensation Expense | 22,847,000 | 37,809,000 | 41,410,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 101,023,000 | 15,969,000 | -8,997,000 |
| Change In Inventories | -14,782,000 | -45,086,000 | -14,109,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 7,345,000 | -26,025,000 | -76,426,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 582,933,000 | 628,299,000 | 91,272,000 |
| Purchases Of Marketable Securities | 0 | 0 | 6,300,000 |
| Sales Of Marketable Securities | 0 | 710,000,000 | — |
| Acquisition Of Property Plant And Equipment | 73,522,000 | 86,648,000 | 81,368,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -17,353,000 | 776,162,000 | 1,313,524,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 820,815,000 | 369,578,000 | 388,882,000 |
| Issuance Of Long Term Debt | — | 0 | 0 |
| Repayment Of Long Term Debt | — | 0 | 0 |
| Other Financing Activities | 2,925,000 | 7,701,000 | 4,344,000 |
| Cash From Financing Activities | -857,523,000 | -1,128,235,000 | -947,121,000 |
| Change In Cash | -243,422,000 | 250,079,000 | 443,627,000 |
| Cash At End Of Period | 919,860,000 | 1,163,396,000 | 913,163,000 |
| Income Taxes Paid | 131,350,000 | 154,876,000 | 359,800,000 |
| Interest Paid | 86,195,000 | 91,092,000 | 94,008,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 2.07 | 2.21 | 5.56 |
| Price To Earnings Ratio | 46.913 | 50.3665 | 19.6601 |
| Earnings Growth Rate | -6.3348 | -60.2518 | 23.2816 |
| Price Earnings To Growth Ratio | -7.4056 | -0.8359 | 0.8444 |
| Book Value Per Share | 62.2124 | 62.4562 | 63.1314 |
| Price To Book Ratio | 1.5609 | 1.7822 | 1.7315 |
| Ebitda | 866,249,000 | 883,725,000 | 1,602,249,000 |
| Enterprise Value | 13,617,597,620 | 15,651,292,360 | 17,339,745,240 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.4441 | 0.411 | 0.587 |
| Capital Expenditures | 402,372,000 | 400,412,000 | 458,473,000 |
| Free Cash Flow | 180,561,000 | 227,887,000 | -367,201,000 |
| Return On Equity | 0.0333 | 0.0353 | 0.088 |
| One Year Beta | 1.1198 | 0.8729 | 0.8633 |
| Three Year Beta | 0.996 | 1.0406 | 1.0148 |
| Five Year Beta | 1.0213 | 0.8654 | 0.901 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Victor Miriame | — | 2026-02-24 | 1,862 | A | 19,984 |
| Victor Miriame | — | 2026-02-24 | 1,862 | D | 18,122 |
| Victor Miriame | — | 2026-02-24 | 1,862 | A | 0 |
| McMurry-Heath Michelle | Director | 2026-02-23 | 600 | D | 4,233 |
| Singh Prahlad R. | Director | 2026-02-17 | 6,901 | D | 113,312 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | 2025-10-10 | CA31 | Purchase | 2025-09-12 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-09-12 | CA31 | Purchase | 2025-08-13 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-08-14 | CA31 | Purchase | 2025-07-23 | — | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-06-17 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Sale (Partial) | 2025-07-22 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| FIRST NATIONAL BANK OF OMAHA | 2025-12-31 | 6,584,998 | 68,062 | 96.75 |
| Dynamic Technology Lab Private Ltd | 2025-12-31 | 807,000 | 8,345 | 96.7046 |
| Y-Intercept (Hong Kong) Ltd | 2025-12-31 | 982,883 | 10,159 | 96.75 |
| Pinnacle Wealth Planning Services, Inc. | 2025-12-31 | 34,250 | 354 | 96.7514 |
| QUADRANT CAPITAL GROUP LLC | 2025-12-31 | 48,472 | 501 | 96.7505 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| PIMCO Equity Series | 2025-12-31 | Class A | PMJAX | 21,005 | 2,032,233.75 | 0.0676 |
| PIMCO Equity Series | 2025-12-31 | I-2 | PMJPX | 21,005 | 2,032,233.75 | 0.0676 |
| PIMCO Equity Series | 2025-12-31 | Institutional Class | PMJIX | 21,005 | 2,032,233.75 | 0.0676 |
| PIMCO Equity Series | 2025-12-31 | PIMCO RAFI Dynamic Multi-Factor U.S. Equity ETF | MFUS | 372 | 35,991 | 0.0171 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class H | RYNHX | 403 | 38,990.25 | 0.015 |